Cambridge biopharma company Microbiotica reveals that the first patient has been dosed in its Phase 1b First-in-Human trial, ...

Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that the first patient has been ...

Structure Therapeutics (GPCR) announced the first patients have been dosed in the randomized, double-blind, placebo-controlled Phase 2b ACCESS ...

Comprehensive development program also includes Phase 2 ACCESS II study to evaluate even higher doses of GSBR-1290 over 36 weeks; first patient expected to be dosed by end of 2024 ...

Ankyra Therapeutics has announced the dosing of the first patient with a visceral tumour in part two of its Phase I clinical ...

The phase 2 INVINCIBLE-4 clinical trial is currently underway in patients with localized triple-negative breast cancer.

Quotient Sciences and MMV’s trial is dosing participants with what they claim is first ever long-acting injectable for ...

The initial trio of patients with glioblastoma have begun treatment with ropidoxuridine in a phase 2 clinical trial, ...

05, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse ...

Detailed price information for Palisade Bio Inc (PALI-Q) from The Globe and Mail including charting and trades.

today announced that it dosed its first subject in its Phase 1 clinical study of PALI-2108, an orally administered PDE4 inhibitor prodrug that is locally bioactivated in the colon and is in ...

(NASDAQ: IBRX), announced today that the first patients have been dosed in an initial trial studying the potential of the company’s CAR-NK cell therapy targeting CD-19 in the treatment of non ...